glp-1 safety Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of receptor agonist efficacy and Efficacy and Safety of GLP-1
Description
Appetite suppressants are restricted due to the adverse neurological effects they can cause
GLP-1RAs and their impact on eating disorder psychopathology GLP-1RAs are not approved for treating eating disorder psychopathology
Products from such sources may be contaminated, improperly dosed, or counterfeit
6.010.8% weight loss) compared to placebo (3.0% weight loss [3.3 kg]
When both medications are taken together, the appetite-suppressing effects can become quite pronounced
